# ANGELMAN SYNDROME GENETICS 101

Rebecca D Burdine, PhD and mom to Sophie 14yo del+


<u>Current Disclosures:</u> ASF Board Member ASF Scientific Advisory Committee OVID Clinical Trial Steering committee (STARS/ELARA/NEPTUNE)




## **TODAY'S PRESENTATION**

- Overview of genetics behind Angelman Syndrome
- Brief discussion of genotype/phenotypes in AS
- Where should I focus as a beginner?
- Why do we think better therapeutics are possible?
- What do I need to know about clinical trials in general?


#### WE HAVE 23 PAIRS OF CHROMOSOMES IN OUR CELLS




#### **GENES** ENCODE INSTRUCTIONS FOR MAKING **PROTEINS**




#### WE RECEIVE ONE SET OF CHROMOSOMES FROM MOM AND ONE SET FROM DAD




#### ANGELMAN SYNDROME IS CAUSED BY A LOSS OF FUNCTION UBE3A IN THE BRAIN




#### UBE3A MARKS PROTEINS FOR RECYCLING OR REMOVAL (DEGRADATION)



#### KNOWN MECHANISMS THAT RESULT IN ANGELMAN SYNDROME



### MICRODELETIONS IN AS




http://www.imprinting-disorders.eu/?page\_id=276


Class I deletions are ~6MB


Human Genome is 3235 MB with around 20,000 genes

#### KNOWN MECHANISMS THAT RESULT IN ANGELMAN SYNDROME




#### GENETICS 201 - MUTATIONS CHANGE GENE INFORMATION AND THE RESULTING PROTEIN PRODUCED






The UBE3A gene encodes a protein called a ubiquitin ligase.

#### KNOWN MECHANISMS THAT RESULT IN ANGELMAN SYNDROME




#### YOUR CELLS KNOW WHICH CHROMOSOME CAME FROM MOM AND WHICH CAME FROM DAD




**Chamberlain and Lalande J. Neurosci 2010** 

#### FIRST IMPLICATIONS OF GENOMIC IMPRINTING IN DISEASE



#### UPD = uniparental disomy

#### KNOWN MECHANISMS THAT RESULT IN ANGELMAN SYNDROME



# SYMPTOMS OF AS

**Consistent** 

- Predominantly non-verbal
- Movement/Balance Issues
- Skill development is delayed
- EEG Abnormalities
- <u>Frequent</u>
- Seizures

#### <u>Associated</u>

- 🛛 Anxiety
- **Sleep issues**
- **GI** issues reflux and constipation
- **Feeding issues over eating or lack of appetite**
- Drooling/mouthing behaviors
- □ Aggression disruptive behaviors
- Myoclonus tremoring

#### IN GENERAL....

- Deletion Class I
- Deletion Class II
- Mutation
- UPD
- ICD/Imprinting defect
- Mosaic forms of the above

**Decreasing Severity** 

### SO WHAT CAUSES MY LOVED ONES SYMPTOMS?

We know that all of the unique symptoms of AS – impaired verbal communication, motor issues, seizures, generally pleasant demeanor are all from loss of UBE3A.

Remember – there are ~20,000 other genes that contribute to who our loved ones are!

#### WHAT ARE MY PRIORITIES FOR MY CHILD?

- 1. Health (seizures, reflux, GI issues)
- 2. Communication
- 3. Behaviors (including sleep!)

## WHAT ARE MY PRIORITIES FOR ME AS A CAREGIVER?

# 1. Health (mental, physical – reduce stress and guilt)

2. Sleep


3. Community

#### WE RECEIVE ONE SET OF CHROMOSOMES FROM MOM AND


ONE SET FROM DAD







The egg that developed into your child was created when you/mom was still in utero



#### WORDS MATTER

#### Don't take it personally – but educate....

Strongly affected by AS VS. Less affected by AS Severe, low functioning Less severe, higher functioning

- Onset of seizures: ~7 months
- Sitting up without support: 3-4 years, currently can sit for 30 minutes with protection
- Walking: with support only
- Number of seizure drugs: Current 2 tried 6
- Bayley's: lowest possible score



#### **INFORMATION BREAK!**


#### WHAT QUESTIONS DO YOU HAVE SO FAR?



## WHAT THERAPEUTICS ARE CURRENTLY AVAILABLE FOR ANGELMAN SYNDROME?

- Epilepsy (AEDs, diet)
- Sleep (medicine, behavioral therapies)
- Reflux (medications such as Prevacid)
- Behavior (Behavioral Therapies, anxiety medications)
- Motor issues (Physical/Occupational Therapy)
- Communication (IPAD, education, Speech Therapy)

## DEVELOPMENT OF THERAPEUTICS IN ANGELMAN SYNDROME



STRATEGIES:

- 1) Replace UBE3A in neurons
  - Viral delivery of UBE3A gene
  - Activate the silent paternal UBE3A gene using ASOs/LNAs/CRISPR
- 2) Correct neuronal function in the absence of UBE3A
  - Find drugs/compounds that improve neuronal function

\*Please see Industry Updates Video for details! https://www.angelman.org/events/asf-virtualpalooza/

AS = loss of UBE3A function in neurons

#### IS IT REASONABLE TO THINK TARGETED THERAPEUTICS ARE POSSIBLE? 3 EXAMPLES

- 1. Modifications in CamKII rescued the phenotypes of the AS mouse (van Woerden et al. 2007)
- CamKII is predominantly expressed in the brain AFTER birth suggesting AS does not cause defects in brain development.
- 2. Restoring Ube3a to the adult AS mouse brain rescued many phenotypes (Daly et al. 2011; Silva-Santos et al. 2015)
- 3. While a one study suggests rescue of some phenotypes may require early interventions, others (neural plasticity) could be rescued at any age. (Silva-Santos et al. 2015)

#### **BOTTOM LINE**




If you are a mouse with Angelman Syndrome, I have very good news for you! \*

Mice aren't humans. But there is reason to believe targeted therapeutics are possible, and we won't know until we know. And to know, we need clinical trials.

\* Shout out to the late Dr. Judah Folkman for this quip

## PHASES OF TESTING INTERVENTIONS/THERAPEUTICS




#### WHAT ARE OUTCOME MEASURES?

igodol




- Tests that accurately assess function at baseline before treatment.
- Can be used during and after treatment to assess change/efficacy.

#### VERY BASIC TRIAL DESIGN




#### WHY DO WE NEED PLACEBO CONTROLLED TRIALS?

AKA: I know myself and I know my child



#### WHY DO WE NEED PLACEBO CONTROLLED TRIALS?



#### THE FLIP SIDE OF THE PLACEBO




## Nocebo:

A harmless thing that causes harm because you believe it's harmful

## SO WHAT DO WE DO?



#### WHAT ARE SOME OF THE DIFFICULTIES?



## WHAT ARE SOME OF THE DIFFICULTIES?

#### TABLE II. 2005: Clinical Features of AS

A. Consistent (100%)

- Developmental delay, functionally severe
- Movement or balance disorder, usually ataxia of gait, and/or tremulous movement of limbs. Movement disorder can be mild. May not appear as frank ataxia but can be forward lurching, unsteadiness, clumsiness, or quick, jerky motions
- Behavioral uniqueness: any combination of frequent laughter/smiling; apparent happy demeanor; easily excitable personality, often with uplifted hand-fla
- Speech impairme
- B. Frequent (more that
  - Delayed, disprop Microcephaly is 1
  - Seizures, onset u
  - Abnormal EEG, v precede clinical f
- C. Associated (20%-80
  - Flat occiput
  - Occipital groove
  - Protruding tongu
  - Tongue thrusting
  - Feeding problem
  - Prognathia
  - Wide mouth, wid
  - Frequent droolin
  - Excessive chewir
  - Strabismus
  - Hypopigmented
  - Hyperactive lowe
  - Uplifted, flexed arm position especially during ambulation
  - · Wide-based gait with pronated or valgus-positioned ankles
  - Increased sensitivity to heat
  - · Abnormal sleep-wake cycles and diminished need for sleep
  - · Attraction to/fascination with water; fascination with crinkly items such as certain papers and plastics
  - Abnormal food related behaviors
  - Obesity (in the older child)
  - Scoliosis
  - Constipation

erbal ones

C) by age 2 years.

hroughout adulthood 2 years of life and can

#### THE HOMOGENEITY OF DIVERSITY



# WHAT CAN THE AS COMMUNITY DO? Get Informed about trials in general



· Diversity in Clinical Trial Participation



www.fda.gov/forpatients/clinicaltrials

#### www.angelmanclinicaltrials.com

## WHAT CAN THE AS COMMUNITY DO?

# PARTICIPATE!

- Save medical records
- Visit AS Clinics
- Participate in Natural History Studies
- Participate in surveys
- Contribute to ongoing studies and trials
- ALWAYS CONSULT YOUR MEDICAL CARE PROVIDER ABOUT STUDIES!
- READ ALL THE PAPERWORK!



# WHAT CAN THE AS COMMUNITY DO?

## PARTICIPATE! - ClinicalTrials.gov

linicalTr	ials.gov										Sevent Shuders (2)
service of the U.S. N	valoral institutes of Plants										Olio is herees
Find Studies -	About Studies - 3-	abelit Bisdies .*	Rescort	1017	Abs	out Site +					
Hang I Scarpt Revu		and Dates					Search Condition / Disease Condition / Disease Other Ierras Country	Amerik Appled Malo Havin Di S Stu	drome x x x Advanced Search Taw ≠ Rounding as Rearch Trends: Closeling tieles found for: les   Angeliman Syndrome	© Sumita	<ul> <li>Subsolut to R55</li> </ul>
Filtery											Showintoe Columns
T MARKED	Clear		1	Row 1	Saved	Status	Musly Title		Candillana		arveitions
Status	[Lease		•	1	8	family.	A New Colorin With Experimentations		Angeimen Syndrome	Drug: OV101 Reg Drug: OV101 reg	mar 1. mar 2. Ottar: Piscelo
Studies:			-	2	11	Recycles.	Single Dose Prometochem (Pro Duce		Argeiman Byrdrome. Pagle X Byrdrome	Drug DV101	
Recruiting				3	4	Renders	Staff datest Microcenter and Analpholy Registry (DMART	1	25411 Dealon Syrbona, Didange Syrbona, Trasny 21. Trasmy 18. Trasmy 19. Monoasny 3. Bao Chumosome Anamattas, Ch Chat Syrbona, Angeman Syrbona, Propanikis Syrbona, 1535 Dealon Syrbona,	6	
E Enroling by init G Active, mit recru Suspended				<u>*</u>	8	Anney	Development of the screament President Test for Microsoftware Represented Report on Cold Press (2016)	and Directions	Morpheeden Synthemes: Traciny 21, Traciny 18, Traciny 18, Sec. Orientecore Advantatives		
E Terminated				8	8	Renverg	Development of Non-Inclusive Prevales Dowering Test for Mo on Field DIAA Secret From Material Doot	constant Direct	Treony 21. Traoiny IE. Traoiny IE. Bex Divorceone Abramatices. Morposation Epinoromea		
Withdrawe     Unknown status     Expanded Administ				3	(Renzi		tes ( Angentius Syndrom) found only a few studies.				

Signup for newsletters from parent support organizations

Follow companies on social media

Get involved in the Facebook Communities

### WHAT CAN THE AS COMMUNITY DO?

Think community-wide

Don't get in our own way.....

## THANK YOU!